Epigenica’s CSO and co-founder Simon Elsässer was interviewed by Swedish TV4 to help viewers better understand click chemistry and the implications of this year’s winner of the Nobel Prize in Chemistry.
Epigenica were happy to attend the Nordic Life Science Days 29-30th November. Thank you to all interesting people who met our representatives during the conference – both in one-on-one partnering meetings and during the networking events.
Epigenica is attended the Nordic Innovation Fair 2022 and became the Top Pitching case in its session.
Epigenica is chosen to attend the Nordic Innovation Fair on the 26th-27th of September, as one of the 30 most promising business opportunities.
Epigenica is happy to have joined the DRIVE Business Incubator at Karolinska Institutet Innovation. DRIVE is a dedicated life science incubator program which supports successful commercial development of businesses.
Epigenica has been awarded a Proof-of-Concept grant of €150,000 to begin commercialization of a new platform technology. The ERC PoC hmqPro will focus on developing novel highly-multiplexed, quantitative biomarker profiling.
ALMI Innovation has provided seed funding for Epigenica to develop the company IP portfolio.
KI Innovation has provided seed funding for Epigenica to develop the company IP portfolio.
A Proof-of-Concept grant from the European Research Council (€150,000) marks the start of Epigenica and will allow Epigenica to further develop the platform and shorten our road to reach the market.